GW26-e2958 To study involvement of serum matrix metalloproteinase-9 in pathogenesis of myocardial infarction  by Tserendavaa, Sumiya et al.
C158 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 6 , S U P P L S , 2 0 1 5matching analysis, compare the relationship beween the changes of
MPV, P-LCR after treatment and MACE events.
RESULTS 1. MPV and P-LCR, were higher in ACS group than the
control group (P < 0.05), in the control group, UA group, STEMI
and NSTEMI group showed a trend of rising (P < 0.05). 2.
Spearman correlation analysis: the MPV, P-LCR and Gensini score
were positively correlated. Multiariable Logistic regression analysis
shows MPV, P-LCR is a risk factor for the ACS.3. In the follow-up
period, there are a total of 25 cases MACE incident, including 14
cases of recurrence of angina, 8 cases of recurrence myocardial
infarction and line again revascularization, 3 cases of stent
thrombosis, 0 cases died。Follow-up results show that the MPV, P-
LCR fell more obviously in the non-MACE group, when compared
with the MACE group, the difference was statistically signiﬁcant
(P < 0.05).
CONCLUSIONS 1. The research shows that MPV and P - the LCR
elevated in patients with ACS, more obviously in patients with
myocardial infarction, prompt platelet volume change was associated
with disease severity of ACS.2. The change of MPV, P –LCR were
positively correlated with Gensini score, which can reﬂect the severity
of coronary artery lesions.3. Follow-up results showed that MPV, P -
the LCR drops more apparent in non-MACE group, prompt platelet
volume changes were associated with MACE events within six
months.GW26-e1418
Expression And Clinical Signiﬁcance of IL-25 In The Serum Of Patients With
Acute Coronary Syndrome
Dongxu Sun, Ming Zhu, Tianyi Song, Xin Sun
Beihua University
OBJECTIVES The objective of this study is to determine IL-25
expression in the serum of patients with ACS and its clinical
signiﬁcance.
METHODS Blood samples for serum detection were collected from 60
ACS patients ( including 20 STEMI, 10 NSTEMI, 11 UAP ), 20 SAP and 30
healthy volunteers from Afﬁliated Hospital of Beihua University and
Jilin Central Hospital from September, 2012 to November 12th, 2013.
The serum levels of IL-25 was measure by ELISA. They were divided
into three groups according to the number of coronary artery stenosis:
single vessel disease group, double vessel disease group and multi
vessel disease group. Recorded their general information and the data
of relevant clinical. Experimental data were processed by SPSS 17.0
statistical analysis software. A value of P <0.05 was considered sta-
tistically signiﬁcant.
RESULTS 1. The serum of IL-25 in ACS: Signiﬁcant differences in IL-25
found between ACS group and SAP group, normal group ( P<0.05);
No signiﬁcant differences in IL-25 found between SAP group and
normal group ( P>0.05 ).
2. The serum of IL-25 in different types of ACS: Signiﬁcant differ-
ences in IL-25 found between STEMI group and NSTEMI group, UAP
group ( P<0.05); No signiﬁcant differences in IL-25 found between
NSTEMI group and UAP group ( P>0.05 ).
3. There is a correlation between level of IL-25 and CRP ( r¼0.513,
P<0.05 ).
4. There is a correlation between level of IL-25 and TnI ( r¼0.432,
P<0.05 ).
5. No signiﬁcant differences in IL-25 found between coronary
vascular lesion count ( P>0.05 ).
CONCLUSIONS 1. The level of IL-25 in patients of ACS were much
higher than SAP group and normal group, special much higher in
patients of STEMI, and there is a correlation between level of CRP
and TnI, it can offer us a new idea about the development of ACS in
IL-25.
2. IL-25 as a mark can be used as serological indexes detect the
condition changes of ACS. It has a certain value to diagnosis the ACS.
3. It is the ﬁrst time found the serum level of IL-25 in patients of
ACS, the serum level of IL-25 much higher in patients of ACS, and
there is a correlation between level of CRP and TnI, but no signiﬁcant
differences in IL-25 found between coronary vascular lesion count, so
it can be a mark to diagnosis the ACS.
4. This study demonstrated that the serum level of IL-25 much
higher in patients of inﬂammatory diseases like Lung infection,Asthma, Intestinal inﬂammation and so on. But we cannot ﬁnd the
relationship between IL-25 and ACS. So this study takes a new way of
mechanism and relationship on inﬂammation and ACS.
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Risk of hemorrhagic and ischemic stroke for dual antiplatelet therapy and
new generation oral anticoagulants in patients with acute coronary
syndrome
Fei Gao, Hua Shen, Zhijian Wang, Shiwei Yang, Xiaoli Liu, Yujie Zhou,
Yujie Zhou
Department of Cardiology, An Zhen Hospital, Capital Medical
University, Beijing, China
OBJECTIVES The overall risk–beneﬁt proﬁle of new generation oral
anticoagulants (NOAC) in addition to antiplatelet therapy on hemor-
rhagic as well as ischemic stroke for patients with acute coronary
syndrome (ACS) has not been clearly established.
METHODS Studies evaluating clinical outcomes of NOAC (including
direct Xa inhibitors, direct thrombin inhibitors and PAR-1 antagonists)
in addition to standard antiplatelet therapy in patients with recent
ACS, published before Nov 2014, were screen. Eleven double blind,
placebo-controlled, randomized clinical studies including 46782 pa-
tients were identiﬁed.
RESULTS The study revealed a 3-fold increased risk of hemorrhagic
stroke in patients receiving NOAC in addition to antiplatelet therapy
compared to those without NOAC (OR 3.04, 95% CI 1.77 to 5.25,
P <0.0001). There was also a signiﬁcantly increased risk of major
bleeding in patients receiving NOAC (OR 2.45, 95% CI 1.58 to 3.80,
P <0.0001). However, the use of NOAC was associated with a signiﬁ-
cantly reduced risk of ischemic stroke (OR 0.79, 95% CI 0.64 to 0.99,
P ¼0.04) and composite efﬁcacy outcome (death/myocardial infarc-
tion/stroke) (OR 0.87, 95% CI 0.81 to 0.93, P <0.0001). There was also
a borderline signiﬁcant reduction in all-cause mortality (OR 0.91, 95%
CI 0.82 to 1.00, P¼0.05) in favor of NOAC therapy.
CONCLUSIONS In patients with ACS, the addition of NOAC to an-
tiplatelet therapy led to a modest but signiﬁcant reduction in
ischemic stroke and overall composite efﬁcacy outcome at the cost
of a substantial increase in hemorrhagic stroke and major bleeding
events.
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To study involvement of serum matrix metalloproteinase-9 in
pathogenesis of myocardial infarction
Sumiya Tserendavaa,2,1 Odkhuu Enkhtaivan,1,1 Zorigoo Shagdar,2,2
Munkhzol Malchinkhuu1,1
1Mongolian National University of Medical Science; 2Ulaanbaatar
Songdo Hospital
OBJECTIVES To study the involvement of serum MMP-9 enzyme in
the pathogenesis during the rupture of the coronary atherosclerosis
plaque.
METHODS The study was conducted using case-control design. The
main inclusion criteria of the case group is that the patient should
have a ruptured coronary atherosclerotic plaque, conﬁrmed by angi-
ography. The total number of patients is 80, half of them belongs to
the case group. MMP-9 is was determined in serum by ELISA. We used
CIIS (cardiac infarction injury score) by ECG and Gensini score system
(Coronary Angiographic Scoring System) for assessing the severity of
coronary heart disease.
RESULTS The average level of MMP-9 in case and control groups are
0.3960.155 ng/ml, 0.2230.087 ng/ml respectively with p<0.001
signiﬁcance which shows MMP-9 (OR¼0.001, p<0.001) may plays a
role in the pathogenesis of plaque rupture. MMP-9 is correlated with
Gensini score and CIIS score, respectively (r¼0.552, p<0.01; r¼0.340,
p<0.01) which shows MMP-9 is being elevated with the increase of the
severity of coronary heart disease and the cardiac infarction injury.
Serum MMP-9 increases statistically signiﬁcantly (p<0.001) with the
increase of the severity of the stenosis and the number of the affected
arteries: no severe stenosis (<75% stenosis) (0.2450.086 ng/ml); 1
vessel severe(>75%) stenosis (0.3170.132 ng/ml), 2 vessel severe
stenosis (0.3480.157 ng/ml), 3 vessel severe stenosis (0.4220.112
ng/ml).
Furthermore, serum MMP-9 enzyme increases with accordance of
severity of the myocardium injury with the statistical signiﬁcance
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ml), possible injury (CIIS 10-15, 0.3170.132 ng/ml), probable injury
(CIIS >15, 0.3760.132 ng/ml) group. MMP-9 levels were signiﬁcantly
higher in the probable injury (CIIS >15) patients compared to the
possible injury (CIIS 10-15) patients (p < 0.001).
CONCLUSIONS An increase in serum MMP-9 enzyme levels is a risk
factor of the coronary atherosclerotic plaque rupture (OR¼0.001,
p<0.001).GW26-e3856
Danhong Injection (A Traditional Chinese Patent Medicine) for Acute
Myocardial Infarction: A Systematic Review and Meta-analysis
Pengda Liao,1,1 Lei Wang,1,2 Minzhou Zhang,1 Liheng Guo,1
Juming Huang,1,2 Ruixiang Zeng1,2
1Guangdong Provincial Hospital of Chinese Medicine, Guangzhou
51020, China; 2The 2nd Clinical College of Guangzhou University of
Traditional Chinese Medicine, Guangzhou 51020, China
OBJECTIVES Acute myocardial infarction (AMI) is a critical global
health problem. Therefore, new medicines and advanced treatments
with less side-effect or complication are needed. Previous studies
suggested that Danhong injection (DHI) might be an effective medi-
cine in AMI treatment. However, its efﬁcacy and safety have not yet
been systematically evaluated. So we aimed to systematically assess
the efﬁcacy and safety of DHI for AMI patients.
METHODS We searched several electrical databases and hand-
searched several Chinese medical journals. Randomized controlled
trials (RCTs) comparing DHI plus conventional western medicine with
conventional western medicine plus placebo and RCTs comparing DHI
plus conventional western medicine with conventional western
medicine were retrieved. Study screening, data extraction, quality
assessment and data analysis were conducted in accordance with the
Cochrane standards.
RESULTS 13 RCTs enrolling 979 patients were included. Danhong in-
jection could signiﬁcantly reduce the risk of mortality, recurrent
angina, arrhythmia, and heart failure. In addition, Danhong injection
was associated with improvement of left ventricular ejection fraction
(LVEF) and reperfusion. However, the safety of DHI remained un-
known for limited data.
CONCLUSIONS Danhong injection might be a potentially efﬁcacious
treatment for AMI patients. Nevertheless, the safety of Danhong in-
jection remained uncertain for limited information. Due to the overall
quality of all included studies is generally low, more high quality RCTs
are expected to validate the efﬁcacy and safety of DHI for AMI
patients.GW26-e5333
Comparison Long-term Outcomes of Conservative vs PCI Treatment in
NSTE-ACS Patients with Intermediate Coronary Stenosis
Muyang Yan
PLA General Hospital
OBJECTIVES (1) To evaluate the clinical outcomes of patients with
intermediate coronary lesions, comparing those who underwent PCI
for the intermediate lesion to those who did not (MT);
(2) to determine the predictive factors of major adverse clinical
cardiac events (MACE) in follow-ups.
METHODS A total of 222 patients (mean age 6310 years), with non-ST
segment elevation acute coronary syndrome (UA/NSTMI) who had at
last one intermediate coronary lesions (diameter stenosis rate 40-
70%) were included in the study. PCI of an intermediate lesion was
underwent in a group of 110 patients (PCI group). And the other 112
patients were treated with medical treatment by guideline (MT
group). In all patients serious coronary lesions (diameter stenosis
rate 70%) were treated with PCI. MACE (cardiac death, nonfatal
myocardial infarction, a need for target lesion revascularization) and
the presence of angina were evaluated in follow-ups.
RESULTS There was no difference regarding the mean percent
diameter stenosis (54.79.3% and 54.66.8%, P <0.01) between the
two groups. The clinical features between two groups are similar.
Although With the similar secondary prevention of coronary heart
disease, quiting smoking, regular exercise, having clopidogrel andstatins using, and dyslipidemia controlling were higher in the PCI
group compared with MT group (P <0.05). At a mean follow - up of
3011 months, the tolal occurrence of MACE and presence of angina
were similar between groups. PCI group with moderate TIMI risk has
more incidence of TLR than MT group. TIMI risk score is a predictive
factor of MACE (hazard ratio 1.38, 95% CI 1.057–1.800, P < 0.05).
CONCLUSIONS (1) In patients with UA/NSTMI, PCI for intermediate
coronary lesions did not reduce the occurrence of angina and MACE,
especially in those with moderate TIMI risk.
(2) TIMI score is a very powerful predictive factor for long prognosis
in UA/NSTMI patients.
(3) The secondary prevention of coronary heart disease and medical
treatments should be emphasized.GW26-e1376
The change of plasma B type natriuretic peptide level in patients with
acute myocardial infarction and its meaning.
Ru Zhao, Hongliang Cong
Tianjin chest hospital, Tianjin 300222, P.R.China
OBJECTIVES To observe the change of plasma BNP level, and the
relationship between it and reconstruction and prognosis in patients
with acute myocardial infarction undergoing early intervention
treatment.
METHODS Choose 114 cases of hospitalized patients with initial AMI,
all underwent emergency percutaneous coronary intervention (PCI),
infarction related artery (IRA) opened in 69 cases (opened group), did
not open in 43 cases (not opened group). On admission to detect
myocardial injury markers [CK, CK - MB, troponin I (cTnI)], to mea-
sure left ventricular ejection fraction (LVEF), left ventricular end-
diastolic volume index (LVEDVI) on the seventh day of admission by
using ultrasound. TO measure the level of BNP in plasma on admis-
sion, 24 h after AMI, the seventh day of admission (marked them as
BNP1 BNP2 BNP3 respectively); Postoperative follow-up of 2 years,
recording the occurrence of major adverse cardiovascular events
(MACE).
RESULTS Comparing serum level of CK, CK - MB, cTnI, TG, LDL - C in
two groups on admission, they all have no signiﬁcant differences (P
> 0.05);7 days after admission, comparing opened group with not
opened group, the level of LVEF increased signiﬁcantly, but LVEDVI
reduced (The former P < 0.05, the latter P > 0.05); BNP1 has no
statistical signiﬁcant differences between the two groups, BNP2
increased signiﬁcantly more than BNP1, BNP3 (P < 0.05), the level of
BNP2, BNP3 increased signiﬁcantly in opened group than not opened
group(P < 0.05). Three time points detection of BNP level and
LVEDVI and CK, CK - MB, cTnI there were positive correlation (P <
0.01). LVEF is negatively related (P < 0.01). the occurrence of MACE
in opened group have 10 cases(14.5%), not opened group have 16
cases(37.2%),(P<0.05); BNP2 predicted MACE within 2 years (cardiac
death, new or worsening heart failure, nonfatal myocardial infarc-
tion) in the area under the ROC curve was 0.791 (p < 0.05), the
boundary value of 332 ng/l, sensitivity was 76.9%, speciﬁcity was
73.3%.
CONCLUSIONS Plasma BNP levels of AMI patients after 24 h
can predict MACE, help to understand LVRM earlier, to prevent or
slow down the occurrence and development of heart failure after
AMI.GW26-e1021
Study of serum ferritin levels in patients of Acute Coronary Syndrom
Tianyu Xiao, Hongyan Wang
the second hospital of dalian medical university
OBJECTIVES To observe the level of SF in patients with
Acute Coronary Syndrome(ACS), and its relation with the severity
of coronary artery lesions, and explore the signiﬁcance of SF in
ACS.
METHODS Collect 126 patients with ACS, and 41 patients conﬁrmed
with cardiac neurosis as control group. The ACS group constituted
with 52 cases of patients with UA, 31 cases of patients with NSTEMI
and 43 cases of patients with STEMI. All patients took blood line for
routine blood, cTNI, CK-MB, BNP and other indicators. SF, lipid, renal
function, and biochemical examination undertook the next day on
